Alector operates as a clinical-stage biopharmaceutical enterprise that typically generates its revenue primarily through multi-year pharmaceutical collaboration agreements, research grants, and licensing partnerships with major drug developers rather than commercialized product sales. Recent quarterly and trailing financial reports indicate that collaboration revenues fluctuate based on milestone achievements and contract timelines, yielding modest quarterly figures around a few million dollars as the firm directs its capital reserves primarily into extensive research and development pipelines.